Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts. Founded in 2014, Compass focuses on developing proprietary antibody-based therapeutics to treat a variety of human diseases, with a strong emphasis on oncology.
The company’s core mission is to thoroughly address the tumor-immune synapse by utilizing combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. Compass industrializes antibody discovery and decentralizes biologic validation through a partnership-first mentality, leveraging best-in-class technologies and top-tier academic laboratories globally. All novel scientific insights are validated extensively within Compass's own labs before proceeding to proprietary combination therapeutics aimed at human clinical trials.
In 2015, Compass secured a $120 million Series A financing to support its ambitious plans to build a fully-integrated biopharmaceutical company. The company’s robust pipeline includes three primary product candidates—CTX-009, CTX-471, and CTX-8371. CTX-009 is a bispecific antibody combining DLL4 and VEGF-A inhibitors, CTX-471 is a CD137 agonist, and CTX-8371 is a PD-1 x PD-L1 bispecific antibody. These candidates are in various stages of clinical development, targeting key pathways in angiogenesis, immune response activation, and immunosuppressive mechanisms within the tumor microenvironment.
Recently, Compass has achieved significant milestones. The company reported top-line data showing promising results in its Phase 2 COMPANION-003 trial and Phase 2/3 COMPANION-002 trial. Additionally, the FDA granted Fast Track Designation to CTX-009 in combination with paclitaxel for metastatic or locally advanced biliary tract cancer. Compass continues to make strides in advancing its product candidates through both standalone therapies and combinations with its proprietary pipeline antibodies.
Financially, Compass maintains a strong position, with a year-end 2023 cash balance of $152 million, extending its cash runway into mid-2026. The company’s net loss for 2023 was $42.5 million, showing a slight increase from the previous year, reflecting its intensified clinical and manufacturing activities.
Looking forward, Compass plans to continue its clinical trials and explore additional therapeutic areas. Key leadership changes and additions, such as the appointment of Vered Bisker-Leib, PhD, as CEO, reflect the company’s commitment to steering towards innovation and growth.
For more detailed and updated information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Compass Therapeutics, Inc. (CMPX) announced the FDA's approval of the investigational new drug application for CTX-009, allowing an expansion to a global Phase 2 study in biliary tract cancer. Interim data indicated a 42% overall response rate (ORR) and a 92% clinical benefit rate (CBR) among the first 24 patients. The CTX-471 Phase 1b study reported 3 partial responses. As of March 31, 2022, the company had $136.4 million in cash, anticipated to fund operations into late 2024, with a reduced net loss of $7.2 million for Q1 2022, compared to $7.3 million in Q1 2021.
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on antibody-based cancer treatments, announced that CEO Thomas J. Schuetz will present at the Bank of America Securities 2022 Healthcare Conference. The event is set for May 12, 2022, at 11:20 AM PT in Las Vegas. The presentation will be available live and replayed 24 hours post-event on the company's website. Compass is dedicated to developing therapies targeting critical biological pathways essential for effective anti-tumor responses.
Compass Therapeutics (Nasdaq: CMPX) announced interim results from its Phase 2 study of CTX-009, revealing a 42% overall response rate (ORR) based on 10 partial responses among 24 patients with biliary tract cancers. The clinical benefit rate reached 92%, with most patients exhibiting stable disease. The drug was well tolerated, aligning with Phase 1 findings. Compass plans to commence the second stage of the study in the U.S. in Q3 2022. The data suggest CTX-009 may offer a new treatment avenue for patients with limited options.
Compass Therapeutics, Inc. (Nasdaq: CMPX) will host a webinar on May 4, 2022, at 8:00 a.m. ET to discuss clinical data from its ongoing Phase 2 trial of CTX-009. A Key Opinion Leader will join the management for this review. The company focuses on developing proprietary antibody-based therapeutics targeting cancer through a unique approach addressing angiogenesis and immune response. The upcoming session aims to provide insights into trial results, with a replay available for six months on the company's website.
Compass Therapeutics, Inc. (Nasdaq: CMPX) announced the appointment of two new directors, Ellen Chiniara and Mary Ann Gray, to its board. Chiniara, former Chief Legal Officer of Alexion Pharmaceuticals, and Gray, President of Gray Strategic Advisors, bring extensive experience in the life sciences and biopharmaceutical sectors. This strategic move aims to enhance Compass's leadership at a critical time for the company. The board believes their skills will support Compass in advancing its clinical pipeline and driving shareholder value.
Compass Therapeutics (CMPX), a clinical-stage oncology company, recently presented promising preclinical data for its bispecific checkpoint inhibitor, CTX-8371, at the AACR Annual Meeting. This innovative therapy targets both PD-1 and PD-L1, showcasing a unique mechanism of action that leads to PD-1 loss on T cells. Key findings indicate significant tumor volume reduction and complete tumor eradication in mouse models. Clinical development of CTX-8371 is projected to start in early 2023, marking a significant step forward in cancer therapeutics.
Compass Therapeutics Inc. (Nasdaq: CMPX) announced its presentation of preclinical data on CTX-8371, a bispecific checkpoint inhibitor targeting PD-1 and PD-L1, at the AACR Annual Meeting from April 8-13, 2022. The study, led by Diana Albu, Ph.D., will showcase the antibody's potential to enhance anti-tumor activity in solid tumors by converting PD-1-positive cells to PD-1-negative cells. As part of IND-enabling preclinical development, CTX-8371 shows promise over existing monoclonal antibodies, indicating its unique mechanism could mitigate immune suppression effectively.
Compass Therapeutics reported a strong financial position with $144.5 million in cash as of 2021, bolstered by a $136 million public offering. The company is advancing its clinical pipeline, particularly the CTX-009 study for advanced biliary tract cancers, which met response criteria for progression to Phase 2. Additionally, CTX-471 showed encouraging results in patients with solid tumors. However, the company faced a net loss of $82.2 million for 2021, with R&D expenses rising significantly to $20.3 million, marking a 36% increase from 2020. The company expects to sustain operations into late 2024.
Compass Therapeutics, Inc. (Nasdaq: CMPX) announced the FDA has cleared its IND application for CTX-009, enabling a global Phase 2 trial for Biliary Tract Cancers (BTC) in the U.S. and South Korea. CTX-009 is a bispecific antibody targeting DLL4 and VEGF-A, showing clinical benefit in heavily pre-treated patients. The ongoing Phase 2 study in South Korea has completed Stage 1, achieving a 29% overall response rate and a 100% clinical benefit rate. Expansion to U.S. sites is planned for Q2 2022, presenting potential growth opportunities for the company.
Compass Therapeutics, Inc. (Nasdaq: CMPX) announced that CEO Thomas Schuetz will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, from 8:15 to 8:55 a.m. ET. The presentation will be virtual, with details to be updated on the company's investor webpage. Compass Therapeutics focuses on antibody-based therapeutics for cancer treatment, exploring the interplay between angiogenesis, the immune system, and tumor growth. Established in 2014 and based in Boston, Massachusetts, the company aims to advance its innovative pipeline through clinical development.
FAQ
What is the current stock price of Compass Therapeutics (CMPX)?
What is the market cap of Compass Therapeutics (CMPX)?
What does Compass Therapeutics, Inc. specialize in?
What are the main product candidates of Compass Therapeutics?
What recent milestones has Compass Therapeutics achieved?
Where is Compass Therapeutics headquartered?
How is Compass Therapeutics financed?
Who are the key executives at Compass Therapeutics?
What is the scientific focus of Compass Therapeutics?
What is the financial condition of Compass Therapeutics?
How does Compass Therapeutics innovate in antibody discovery?
What therapeutic areas is Compass Therapeutics exploring?
